Total R&D costs of select cancer drugs 2017

This statistic shows the total cost of research and development (R&D) for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost of 817.6 million U.S. dollars since R&D start in January 1992.

Total R&D costs for selected cancer drugs on the market as of 2017

Drug name (company, R&D start date)Cost in million U.S. dollars
--
--
--
--
--
--
--
--
--
--
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Sources

Release date

November 2017

Region

United States

Survey time period

as of November 2017

Supplementary notes

This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Clinical trials"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.